Olean Times Herald

Interim Results from FDA-Funded Study Reinforces HyBryte's ™ Rapid Response and Strong Safety Profile PRINCETON, N.J. , April 14, 2025 /PRNewswire/ --...

Broader protection induced by combination of COVID adenovirus vaccine plus CiVax ™ compared to 2-shot mRNA vaccination series PRINCETON, N.J. , March ...

PRINCETON, N.J. , March 21, 2025 /PRNewswire/ --Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focu...

Two Presentations Highlight Data Demonstrating Hypericin Photodynamic Therapy Potential with a Preliminary Comparison to Current Therapy PRINCETON, N....

PRINCETON, N.J. , Feb. 4, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focus...

PRINCETON, N.J. , Jan. 16, 2025 /PRNewswire/ --Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focus...

Study Supported by $2.6 Million FDA Orphan Products Development Grant PRINCETON, N.J. , Jan. 14, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (...

FLASH 2 Study opens patient enrollment PRINCETON, N.J. , Dec. 16, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a la...

Significant Efficacy against Plaque Lesions Also Demonstrated with HyBryte™ PRINCETON, N.J. , Dec. 2, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SN...